Paul Adams, MD
Hematology & Oncology · Flint, MINPI 1811952591
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.1% of the total across 288 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,943, more than ten times the $108 reported in 2019.
Across 288 payments — averaging $20.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$819
- Genentech USA, Inc.$481
- Johnson & Johnson$360
- AstraZeneca$358
- E.r. Squibb & Sons, L.L.C.$208
- Pharmacyclics LLC, An Abbvie Company$197
- plus $3K from 54 others
Across 17 payments — averaging $4141.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$63K
- E.r. Squibb & Sons, L.L.C.$7K
- Merck$96
What the payments were for
- Food & beverage$5,46291%
- Education$5319%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,994 in reported general payments places this provider in the 70th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 75 | $1,662,676 |
| Lenalidomide | 59 | $973,779 |
| XtandiEnzalutamide | 62 | $864,819 |
| VenclextaVenetoclax | 40 | $516,051 |
| OjjaaraMomelotinib Dihydrochloride | 14 | $395,063 |
| CabometyxCabozantinib S-Malate | 14 | $335,883 |
| PomalystPomalidomide | 11 | $284,033 |
| JaypircaPirtobrutinib | 13 | $264,865 |
| TasignaNilotinib Hcl | 12 | $243,865 |
| BrukinsaZanubrutinib | 22 | $236,706 |
| ImbruvicaIbrutinib | 14 | $222,747 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 14 | $93,661 |
| ProcritEpoetin Alfa | 16 | $64,501 |
| OxycontinOxycodone Hcl | 15 | $48,595 |
| CreonLipase/Protease/Amylase | 16 | $38,223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $191 | $1,662,67675 claims |
| Astellas Pharma US IncXtandi | $139 | $864,81962 claims |
| AbbVieVenclexta, Creon | $157 | $554,27456 claims |
| GSKOjjaara | $144 | $395,06314 claims |
| NovartisTasigna, Sandostatin Lar Depot | $819 | $337,52726 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $208 | $284,03311 claims |
| Lilly USA, LLCJaypirca | $49 | $264,86513 claims |
| Beigene USA, Inc.Brukinsa | $90 | $236,70622 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $197 | $222,74714 claims |
| Johnson & JohnsonProcrit, Xarelto | $360 | $91,80633 claims |
| PfizerEliquis | $190 | $37,69835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Flint
- Madan AroraFlint$84K
- Rizwan DanishFlint$43K
- T SinghFlint$9K
- Alyssa KipkeFlint$8K
- Venkatasiva PeramFlint$8K
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Sreenivasa ChandanaGrand Rapids$305K
- Mohammad ChistiTroy$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.